Farma-Biotech promotes nine projects on innovative drugs
Source: redaccionmedica.com
Different Spanish biotechnology companies and research groups presented on Wednesday a total of nine advanced innovative drug development projects to representatives of 17 national and international pharmaceutical companies at a conference organized in Madrid by the Farma-Biotech program of Farmaindustria.
For this seventeenth call and after a careful study of the needs expressed by pharmaceutical companies and the state of development of ongoing research of biotechnology companies and research groups, the Farma-Biotech program selected nine proposals to be presented that address diseases such as multiple sclerosis, cancer, Alzheimer’s or atopic dermatitis.
Six of these nine developments belong to small companies and three to public institutions (a hospital and two research centers). All of them are in advanced stages, have sufficient potential (innovation, efficacy and protection) and their promoters are interested in reaching collaboration agreements with pharmaceutical laboratories that facilitate progress in the final stages of development.
Investment in R & D
The Farma-Biotech cooperation program is part of the Spanish Technological Platform for Innovative Medicines, an initiative of Farmaindustria that has the support of the Ministry of Science, Innovation and Universities. It is a coherent effort with the priorities of the innovative pharmaceutical companies in Spain, whose investment in R & D activities reached 1,147 million euros in 2017.
The figure represents an increase of 5.7 percent over the previous year, confirming the upward trend started four years ago and constitutes a new historical record for the sector, which consolidates its leading position in industrial R & D, since it represents more than 20 percent of the Spanish total.
The largest increase in this investment in R & D corresponded to research projects developed in collaboration with hospitals and public and private research centers (extramural), a chapter that grew by almost 10 percent to reach 542.1 million euros (the 47.2 percent of the total), while intramural investment registered a slight increase of 2.2 percent, to 605.4 million
In Distefar we echo this news that aims to exchange information and knowledge, and that will mean a breakthrough in drugs.
